Matching placebo tablet
Sponsors
Janssen Cilag International, Kubota Vision Inc., Cyclerion Therapeutics, Esperion Therapeutics, Inc., Cedars-Sinai Medical Center
Conditions
CARD9 S12N Risk AlleleCardiovascular DiseasesCrohn DiseaseHealthyMajor Depressive Disorder (MDD) with Moderate-to-severe AnhedoniaStatin Adverse Reaction
Phase 1
Safety and Tolerability of Repeat Doses of ACU-4429 in Healthy Subjects
CompletedNCT00942240
Start: 2009-07-31End: 2010-04-30Updated: 2012-01-10
Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers
CompletedNCT02616861
Start: 2015-11-30End: 2016-06-30Updated: 2019-04-03
Phase 3
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
CompletedNCT02993406
Start: 2016-12-22End: 2022-11-07Updated: 2024-01-03
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open-label Long-term Extension Treatment with Aticaprant
CompletedCTIS2024-511557-21-00
Start: 2024-11-14End: 2025-02-28Target: 212Updated: 2024-11-06
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
CompletedCTIS2024-511057-22-00
Start: 2024-12-04End: 2025-02-28Target: 339Updated: 2024-12-12